Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2018 · 1 min read
In brief
In brief
This case series describes four primary renal CIC-rearranged sarcomas in female patients, characterized by variable histologic patterns and aggressive clinical behavior with lung metastases. Molecular analysis identified CIC-DUX4 and novel CIC-NUTM1 fusions, with distinctive immunohistochemical profiles including WT1 and variable CD99 expression.
Written by the GCMD Library team from the article.
Statements in this article
CIC-rearranged sarcomas rarely occur in visceral organs including the kidney.
The most common fusion partner with CIC is the DUX4 gene, but variant fusion partners have also been reported.
All four cases of primary renal CIC-rearranged sarcoma occurred in females, with an age range of 13 to 82 years.
There was a tendency for development of metastatic disease predominantly to the lungs and poor disease outcome despite different treatment strategies.
Histologically, variable round cell (20% to 100%), spindle cell (0% to 80%), and rhabdoid morphologies (0% to 20%) were seen.
Diffuse WT1 nuclear labeling (2 to 3+, approximately 90%) was present in 1 case, with cytoplasmic staining in the others (3+, 40% to 75%).
CD99 was focally positive in all 4 cases (≤10%).
One case each was diffusely positive for c-myc (2 to 3+, approximately 90%) and ETV4 (3+, approximately 90%).
One case was focally positive for c-myc (2+, approximately 5%) and calretinin (2+, approximately 5%).
All cases were negative for cytokeratin and NKX2.2.
CIC rearrangement by fluorescence in situ hybridization was present in the 3 cases tested.
Comprehensive genomic profiling of 3 cases revealed a CIC-DUX4 fusion in 2 cases and 1 CIC-NUTM1 fusion.
All 4 CIC-rearranged renal sarcomas had low mutation burden.
Except for HLA-A and MLL mutations, the tumors lacked genomic alterations in other oncogenic drivers.